Australia's most trusted
source of pharma news
Saturday, 27 April 2024
Posted 6 October 2020
A US biotech is nearing local registration for its first marketed product in Australia after the TGA granted its Australian subsidiary priority review for its first local offering, belumosudil.
New York-based Kadmon is understood to have registered the business Kadmon Oceania in Australia in August, prior to its first drug even appearing on the ARTG.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.